CHM (ASX) Ann: EMORY JOINS CHM CDH17 PHASE 1/2 CLINICAL TRIAL

Originally posted by NZ Trader: ↑

Brilliant , Organisation is a Non Profit that attracts significant Donations.

https://winshipcancer.emory.edu/about-us/index.phpand they are in Partnership with Who have Partnerships with and Collaborations with

And managed by "I especially like the CEO" he's not all Science ,, he understands Value and Money $$$ NZT

Leadership
Team
Gary Altman, PhD
CEO
Gary is an experienced leader of buy-side and sell-side transactions in life science companies. He is a serial entrepreneur and has held multiple CEO roles. Gary founded, led, and divested companies. At Beckman Coulter he led global market and business development for the $1B Cellular Analysis Business Group.
Ned Waller, MD PhD
Scientific Founder & Chairman
Scientific Advisor, Board Member
Ned received his A.B. from Harvard, a Ph.D. from Rockefeller University, and an M.D. from Cornell University. He completed his Internal Medicine residency and Medical Oncology Fellowship at Stanford and post-doctoral training with Dr. Irv Weissman, focusing on human T-cell development. He has had various leadership roles at Emory University including the Associate Director of Clinical Research for the Winship Cancer Institute, Director of Regenerative Engineering and Medicine, and holds the Rein Saral Professorship in Cancer Medicine. He has built an R01-funded research program in translational and clinical research in cancer immunology. Dr. Waller is a clinician scientist entrepreneur and co-founded Cambium Oncology, a pre-clinical start-up, to develop a novel immune checkpoint drug targeting the receptor for vasoactive intestinal peptide. He serves as the Editor for ImmunoMedicine and chairs the Translational Immuno-Oncology (TIO) study section at the NIH.
Giovanni Selvaggi, MD
Medical Advisor, Board Member
Experienced early/late stage clinical developer based in US with 10+ years of pharmaceutical industry in oncology.Academic and clinical skills in thoracic oncology, Medical Doctor/pulmonologist @Università di Torino in Italy.
Taofeek Owonikoko, MD PhD
Scientific Advisor, Board Member
The main goal for our translational research work is to develop new treatment options for patients with lung cancer and cancer of the thyroid and head and neck. The laboratory effort in this area is focused on understanding the role of immune function in thyroid cancer biology and patient outcome. Our lab also conducts early preclinical and animal studies to explore the efficacy of biologic agents including mTOR inhibitors, PARP inhibitors, Polo like kinase 1 inhibitors and epigenetic targeted therapy.

The result of this preclinical work serve as preliminary evidence of anticancer efficacy that support subsequent testing of the same treatment concept in human subjects. Using this approach, we have successfully advanced several anticancer agents and drug combination from the lab to the clinic using institutional investigator-sponsored trials as well as national cooperative group phase I and phase II clinical trials as vehicle of anticancer drug development.
Terry Walts, MBA
Board Member

Michael Broughton, CPA, CGMA
Michael has served in the audit department of Alumax, now a subsidiary of Alcoa and was a staff accountant with KPMG

His BBA,magna cum laude, is from the University of Notre Dame He is the former CFO of The Georgia Society of Certified Public Accountants as well as the former chair of its Atlanta Chapter. Michael is also a Chartered Global Management Accountant (CGMA) designated by the American Institute of Certified Public Accountants and a judge of the Venture Capital Investment Exercise at the Georgia Tech Scheller College of Business.

Michael currently serves on the boards of directors for the Tucker Professional Association and West Park Properties, LLC. He is a former board member of the Starlight Children’s Foundation of Atlanta and El Matador (Chair of Audit Committee and Treasurer).

Expand

Hi NZT,

This is awesome scientific news.

Emory Winship are smart cookies. They would do a multi layered DD on the whole show.

Their data safety monitoring board would look at all.

I suggest they would have looked for red flags as well.
Protocol deviations, toxicology etc.

A partner like Winship would reject CHM if: Cdh17 expression wasn’t rigorously validated across GI cancer subtypes.

CHM’s focus on clinical biomarkers (CDH17) and their partnership stacks the deck for meaningful data, even in Phase I.

I am highly impressed a highly regarded collaboration.

Very well done team CHM

Kpax